Total Payments
$77,162
2024 Payments
$24,146
Companies
16
Transactions
74
Medicare Patients
487
Medicare Billing
$69,116
Payment Breakdown by Category
Consulting$60,904 (78.9%)
Other$7,085 (9.2%)
Travel$6,391 (8.3%)
Food & Beverage$1,863 (2.4%)
Research$670.30 (0.9%)
Education$250.00 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $60,904 | 23 | 78.9% |
| Travel and Lodging | $6,391 | 23 | 8.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,085 | 2 | 5.3% |
| Honoraria | $3,000 | 1 | 3.9% |
| Food and Beverage | $1,863 | 21 | 2.4% |
| Unspecified | $670.30 | 1 | 0.9% |
| Education | $250.00 | 3 | 0.3% |
Payments by Type
General
$76,492
73 transactions
Research
$670.30
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $23,050 | 17 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $13,125 | 8 | $0 (2024) |
| Sirtex Medical Inc | $6,678 | 4 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $6,292 | 8 | $0 (2024) |
| Advanced Accelerator Applications | $5,644 | 3 | $0 (2020) |
| Exelixis Inc. | $4,087 | 11 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $4,019 | 6 | $0 (2022) |
| Lexicon Pharmaceuticals, Inc. | $3,780 | 1 | $0 (2019) |
| LANTHEUS MEDICAL IMAGING, INC. | $2,835 | 1 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $2,458 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,146 | 29 | Takeda Pharmaceuticals U.S.A., Inc. ($11,156) |
| 2023 | $19,452 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($11,894) |
| 2022 | $3,622 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($2,204) |
| 2021 | $5,469 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($5,469) |
| 2020 | $4,844 | 2 | Advanced Accelerator Applications ($4,844) |
| 2019 | $5,968 | 3 | Lexicon Pharmaceuticals, Inc. ($3,780) |
| 2018 | $4,358 | 5 | Novartis Pharmaceuticals Corporation ($2,545) |
| 2017 | $9,303 | 13 | Novartis Pharmaceuticals Corporation ($5,000) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $1,572.75 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $29.62 | General |
| Category: Oncology | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Consulting Fee | Cash or cash equivalent | $7,590.00 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $681.90 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $332.72 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $207.32 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $199.50 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $132.97 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,910.00 | General |
| 07/09/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,835.00 | General |
| 06/26/2024 | PFIZER INC. | BRAFTOVI (Drug) | Food and Beverage | In-kind items and services | $96.61 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Food and Beverage | In-kind items and services | $118.49 | General |
| Category: Oncology | ||||||
| 05/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $965.13 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $466.71 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $355.00 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $286.77 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $267.10 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $105.13 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $99.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $670.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 145 | 278 | $84,798 | $22,054 |
| 2022 | 2 | 143 | 254 | $73,633 | $19,679 |
| 2021 | 2 | 117 | 226 | $62,070 | $19,038 |
| 2020 | 1 | 82 | 132 | $31,161 | $8,345 |
Total Patients
487
Total Services
890
Medicare Billing
$69,116
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 114 | 247 | $65,614 | $18,099 | 27.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $11,668 | $2,446 | 21.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 14 | 14 | $7,516 | $1,508 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 102 | 212 | $53,916 | $15,691 | 29.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 30 | 30 | $16,705 | $3,119 | 18.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 12 | $3,012 | $869.40 | 28.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 91 | 200 | $49,183 | $16,112 | 32.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 26 | 26 | $12,887 | $2,927 | 22.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 82 | 132 | $31,161 | $8,345 | 26.8% |
About Dr. Arvind Dasari, MD
Dr. Arvind Dasari, MD is a Internal Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1497927123.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arvind Dasari, MD has received a total of $77,162 in payments from pharmaceutical and medical device companies, with $24,146 received in 2024. These payments were reported across 74 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($60,904).
As a Medicare-enrolled provider, Dasari has provided services to 487 Medicare beneficiaries, totaling 890 services with total Medicare billing of $69,116. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Houston, TX
- Active Since 04/02/2008
- Last Updated 06/20/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1497927123
Products in Payments
- FRUZAQLA (Drug) $20,860
- AFINITOR (Drug) $6,875
- SIR-Spheres Microspheres (Device) $6,678
- LUTATHERA (Drug) $4,873
- CABOMETYX (Drug) $4,087
- Stivarga (Drug) $4,072
- Xermelo (Drug) $3,780
- LONSURF (Drug) $2,458
- Nexavar (Drug) $2,220
- SOMATULINE DEPOT (Drug) $2,206
- Somatuline Depot (Drug) $1,813
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $800.00
- SANDOSTATIN (Drug) $670.30
- Lenvima (Drug) $100.00
- BRAFTOVI (Drug) $96.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Houston
Stephen Pappas, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Mohamed Othman, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Aung Naing, Md, MD
Internal Medicine — Payments: $925,146
Internal Medicine $925,146
Miguel Escobar, M.d, M.D
Internal Medicine — Payments: $924,228
Internal Medicine $924,228
Dr. Christie Ballantyne, Md, MD
Internal Medicine — Payments: $815,154
Internal Medicine $815,154
John Heymach, M.d, M.D
Internal Medicine — Payments: $786,947
Internal Medicine $786,947